Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | BTK | Q06187 | 1/20 | 0.36 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.34 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.34 |
| ▸ | RELA | Q04206 | 1/20 | 0.34 |
| ▸ | CTSS | P25774 | 2/20 | 0.34 |
| ▸ | CTSK | P43235 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.33 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 3/20 | 0.33 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.32 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.32 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27872243 | 0.84 | MEN1 (0.43) | KMT2AMEN1MAPK1BTKNFKB1 | |
| SCHEMBL4643135 | 0.84 | MEN1 (0.43) | KMT2AMEN1MAPK1BTKNFKB1 | |
| SCHEMBL28564855 | 0.80 | KMT2A (0.40) | KMT2AMEN1MAPK1BTKNFKB1 | |
| SCHEMBL2630591 | 0.80 | KMT2A (0.40) | KMT2AMEN1MAPK1NFKB1NFKB2 | |
| SCHEMBL12891851 | 0.79 | KMT2A (0.39) | KMT2AMEN1MAPK1BTKCTSS | |
| SCHEMBL1636182 | 0.79 | KMT2A (0.39) | KMT2AMEN1MAPK1BTKCTSS | |
| SCHEMBL6838872 | 0.79 | MEN1 (0.39) | KMT2AMEN1MAPK1BTKNFKB1 | |
| SCHEMBL1687973 | 0.79 | KMT2A (0.39) | KMT2AMEN1MAPK1BTKCTSS | |
| SCHEMBL6838875 | 0.79 | MEN1 (0.39) | KMT2AMEN1MAPK1BTKNFKB1 | |
| SCHEMBL1635700 | 0.79 | KMT2A (0.39) | KMT2AMEN1MAPK1BTKNFKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8163921-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-04-24 | — | — | US | disclosed |
| US-7964560-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-06-21 | — | — | US | disclosed |
| US-7888464-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-02-15 | — | — | US | disclosed |
| US-20090304626-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2009-12-10 | — | — | US | disclosed |
| US-20090274648-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2009-11-05 | — | — | US | disclosed |
| US-20090274652-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2009-11-05 | — | — | US | disclosed |
| US-7323447-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-01-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090304626-A1 | Hepatitis C Virus Inhibitors | HAVCR2, HCCS, PYGL | KMT2A 4486/4885MEN1 4801/4885MAPK1 3159/4885 |
| US-20090274652-A1 | Hepatitis C Virus Inhibitors | HAVCR2, HCCS, PYGL | KMT2A 4486/4885MEN1 4801/4885MAPK1 3159/4885 |
| US-20090274648-A1 | HEPATITIS C VIRUS INHIBITORS | HAVCR2, HCCS, PYGL | KMT2A 4486/4885MEN1 4801/4885MAPK1 3159/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.